Evidence map›Paper›PMID 42598595›Full record

ArticleBlood vessels, thrombosis & hemostasis2026

A rapid ADAMTS13 activity assay using a portable readout device.

Theodora J Steeghs, Nerissa M M Coolen, Elena Krivosheeva, Steven P L Kuijpers, Zixuan Li, Jona Merx, Thomas J Boltje, Nicole M A Blijlevens, Saskia E M Schols, Cornelis van 't Veer and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood vessels, thrombosis & hemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Theodora J SteeghsEnzyre BV, Nijmegen, The Netherlands.
Nerissa M M CoolenEnzyre BV, Nijmegen, The Netherlands.
Elena KrivosheevaEnzyre BV, Nijmegen, The Netherlands.
Steven P L KuijpersEnzyre BV, Nijmegen, The Netherlands.
Zixuan LiDepartment of Synthetic Organic Chemistry, Radboud University, Nijmegen, The Netherlands.
Jona MerxDepartment of Synthetic Organic Chemistry, Radboud University, Nijmegen, The Netherlands.
Thomas J BoltjeDepartment of Synthetic Organic Chemistry, Radboud University, Nijmegen, The Netherlands.
Nicole M A BlijlevensDepartment of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
Saskia E M ScholsDepartment of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
Cornelis van 't VeerEnzyre BV, Nijmegen, The Netherlands.
Waander L van HeerdeEnzyre BV, Nijmegen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a severe type of thrombotic microangiopathy with a high mortality rate. Detection of plasma ADAMTS13 activity levels <0.1 IU/mL confirms the diagnosis of TTP, whereas detection of anti-ADAMTS13 antibodies allows differentiation between congenital TTP and immune-mediated TTP. Unfortunately, turnaround times for ADAMTS13 assays are often long, hampering appropriate treatment decisions. This study describes the design and validation of a microfluidic luminescence-based ADAMTS13 assay (ADAMTS13

Identifiers

PMID42598595
PMCPMC13471944

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.